Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson’s disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial

医学 阶段(地层学) 中医药 血瘀 安慰剂 疾病 内科学 随机对照试验 临床试验 物理疗法 替代医学 病理 古生物学 生物
作者
Yuqing Hu,Si-Chun Gu,Xiaolei Yuan,Hui Li,Can-Xing Yuan,Qing Ye
出处
期刊:Chinese Medicine [Springer Nature]
卷期号:17 (1) 被引量:2
标识
DOI:10.1186/s13020-022-00625-4
摘要

Abstract Background Parkinson’s disease (PD) is a progressive neurodegenerative disease common in aged populations. Classified by Hoehn & Yahr stages, patients are often divided into mild/early stage, moderate/middle stage, and advanced/late stage. With disease progression, PD shows high heterogeneity in each stage. Based on traditional Chinese medicine (TCM) syndrome differentiation theory and our previous works, we found that during the early stage, the main syndrome is Yin deficiency of the liver and kidney; during the moderate stage, the main syndromes are phlegm heat and wind stirring and blood stasis and wind stirring; and during the late stage, the dominant syndromes are deficiency of Yin and Yang and deficiency of Qi and blood. Hence, we proposed a new model of TCM treatment by the stage of PD. Based on Shudi Pingchan formula, an experimental formula of our team, we developed Ziyin Pingchan formula, Jiedu Pingchan formula, and Fuzheng Pingchan formula to treat each stage. This study is designed to evaluate the therapeutic effect of treating Parkinson’s disease by stages using traditional Chinese medicine and to provide an evidence base for forming a standardized scheme of diagnosis and treatment. Methods This study is designed as a multicentre, randomized, double-blind, placebo-controlled clinical trial. Patients will be stratified into 3 subgroups according to Hoehn & Yahr stage; 172, 168, and 72 participants will be required to be in the mild PD, moderate PD, and advanced PD subgroups, respectively, and will be randomized into the treatment or control group at a 1:1 ratio. The mild PD subgroup will receive a 48-week intervention, and the other 2 groups will receive a 24-week intervention. All groups will have a follow-up visit 12 weeks after starting the intervention. The intervention group will receive the Ziyin Pingchan formula, Jiedu Pingchan formula, or Fuzheng Pingchan formula, and the control group will receive the corresponding placebo. The primary outcomes will be the first addition of levodopa for the mild PD subgroup, the duration of the “OFF” period for the moderate PD subgroup, and the Parkinson's Disease Questionnaire (PDQ-39) for the advanced PD subgroup. The secondary outcomes will also be verified by subgroups, including the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Sleep Scale-2 (PDSS-2), scales for Outcomes in Parkinson’s Disease—Autonomic (SCOPA-AUT), and the nonmotor symptom scale (NMSS). Expected outcomes To our knowledge, this is the first trial to combine TCM syndrome differentiation with PD clinical stages and put it into clinical practice. The results of this trial will provide clinical evidence for the therapeutic effect of TCM formulas on PD patients of all stages and help build a new TCM treatment by stage model of PD. Trial registration : This trial is registered at the Chinese Clinical Trial Registry ( http://www.chictr.org.cn/ ). Registration number: ChiCTR2200056373, Date: 2022–02-04, version 1.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LJM完成签到,获得积分10
1秒前
Jasper应助轻松的曲奇采纳,获得10
2秒前
2秒前
Crazy_Runner发布了新的文献求助10
3秒前
MoMo完成签到,获得积分10
5秒前
古药完成签到,获得积分10
5秒前
不挤牙膏发布了新的文献求助10
5秒前
沸点发布了新的文献求助10
6秒前
6秒前
9秒前
WLX完成签到,获得积分10
11秒前
Photon完成签到,获得积分10
12秒前
可耐的三德完成签到 ,获得积分10
12秒前
12秒前
hygge完成签到,获得积分20
13秒前
orixero应助不挤牙膏采纳,获得10
13秒前
13秒前
超帅蛋挞完成签到,获得积分10
13秒前
13秒前
机智向松发布了新的文献求助20
13秒前
14秒前
14秒前
asdfghjkl完成签到,获得积分10
14秒前
15秒前
lslfreedom发布了新的文献求助10
16秒前
深情安青应助沸点采纳,获得10
17秒前
17秒前
王提发布了新的文献求助10
17秒前
wh雨发布了新的文献求助10
17秒前
所所应助jj采纳,获得10
18秒前
清风发布了新的文献求助10
19秒前
彬彬发布了新的文献求助10
19秒前
19秒前
123完成签到,获得积分10
19秒前
20秒前
天天快乐应助迷路博采纳,获得10
21秒前
研友_LMNg6n应助跳跃的邪欢采纳,获得10
21秒前
21秒前
虾米发布了新的文献求助10
22秒前
黎明发布了新的文献求助20
22秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
A Dissection Guide & Atlas to the Rabbit 600
中国心血管健康与疾病报告2023(要完整的报告) 500
Development of a new synthetic process for the synthesis of (S)-methadone and (S)- and (R)-isomethadone as NMDA receptor antagonists for the treatment of depression 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3102795
求助须知:如何正确求助?哪些是违规求助? 2754032
关于积分的说明 7626280
捐赠科研通 2406879
什么是DOI,文献DOI怎么找? 1277068
科研通“疑难数据库(出版商)”最低求助积分说明 617041
版权声明 599103